Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis

Onno W Akkerman, Floris Grasmeijer, Wiel C M de Lange, Huib A M Kerstjens, Gerard de Vries, Mathieu S Bolhuis, Jan-Willem Alffenaar, Henderik W Frijlink, Grace Smith, Roger Gajraj, Rina de Zwaan, Paul Hagedoorn, Martin Dedicoat, Dick van Soolingen, Tjip S van der Werf

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

9 Citations (Scopus)
338 Downloads (Pure)

Abstract

Extensively drug-resistant tuberculosis (XDR-TB) is defined by resistance to isoniazid, rifampicin, any fluoroquinolone and at least one of the three second line injectable drugs, such as amikacin. Drugs toxicity and duration impair adherence to treatment and outcome is rather poor [1]. We report on a particularly challenging XDR-TB patient with persistent non-adherence to treatment and an exceptionally complex drug susceptibility pattern.
Original languageEnglish
Article number1702490
Number of pages4
JournalEuropean Respiratory Journal
Volume51
Issue number3
DOIs
Publication statusPublished - 22-Mar-2018

Keywords

  • MYCOBACTERIUM-TUBERCULOSIS
  • COLISTIN

Fingerprint

Dive into the research topics of 'Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis'. Together they form a unique fingerprint.

Cite this